REG - Competition and Mkts - Merger Update: CSL/uniQure

CSLAnnouncement

06/11/2020 10:05

RNS Number : 4268E
  
Competition and Markets Authority
  
06 November 2020
  
 

Start of CMA Merger Investigation: ANTICIPATED ACQUISITION OF AN INTEREST IN AMT-061 BY CSL BEHRING LLC FROM UNIQURE BIOPHARMA BV
 
The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services. The CMA has reached the preliminary view that this transaction will not result in the creation of a relevant merger situation because it will not result in two or more enterprises ceasing to be distinct.
 
The CMA announced the launch of its merger inquiry by notice to the Parties on 6 November 2020 and has a deadline of Wednesday, 6 January 2021 for its phase 1 decision.
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MERBSBDBUSGDGGU